Objectives: Among the most important diagnostic indicators of colorectal cancer; however, measuring molecular alterations are invasive and expensive. This study aimed to investigate the application of image processing to predict molecular alterations in colorectal cancer.
Methods: In this scoping review, we searched for relevant literature by searching the Web of Science, Scopus, and PubMed databases. The method of selecting the articles and reporting the findings was according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses; moreover, the Strengthening the Reporting of Observational Studies in Epidemiology checklist was used to assess the quality of the studies.
Results: Sixty seven out of 2,223 articles, 67 were relevant to the aim of the study, and finally 41 studies with sufficient quality were reviewed. The prediction of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Neuroblastoma RAS Viral (NRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), Tumor Protein 53 (TP53), Adenomatous Polyposis Coli, and microsatellite instability (MSI) with the help of image analysis has received more attention than other molecular characteristics. The studies used computed tomography (CT), magnetic resonance imaging (MRI), and 18F-FDG positron emission tomography (PET)/CT with radionics and quantitative analysis to predict molecular alterations in colorectal cancer, analyzing features like texture, maximum standard uptake value, and MTV using various statistical methods. In 39 studies, there was a significant relationship between the features extracted from these images and molecular alterations. Different modalities were used to measure the area under the receiver operating characteristic curve for predicting the alterations in KRAS, MSI, BRAF, and TP53, with an average of 78, 81, 80 and 71%, respectively.
Conclusion: This scoping review underscores the potential of radiogenomics in predicting molecular alterations in colorectal cancer through non-invasive imaging modalities, like CT, MRI, and 18F-FDG PET/CT. The analysis of 41 studies showed the appropriate prediction of key alterations, such as KRAS, NRAS, BRAF, TP53, and MSI, highlighting the promise of radionics and texture features in enhancing predictive accuracy.
目的:结直肠癌最重要的诊断指标之一;然而,测量分子变化是侵入性的且昂贵的。本研究旨在探讨图像处理在预测结直肠癌分子变化中的应用。方法:在这篇范围综述中,我们通过检索Web of Science、Scopus和PubMed数据库来检索相关文献。选择文章和报告研究结果的方法按照系统评价和荟萃分析首选报告项目的指南;此外,采用《加强流行病学观察性研究报告》检查表对研究质量进行评估。结果:在2223篇文献中,67篇与研究目的相关,最后41篇质量足够的文献被回顾。利用图像分析预测克尔斯顿大鼠肉瘤病毒癌基因同系物(KRAS)、神经母细胞瘤RAS病毒(NRAS)、B-Raf原癌基因、丝氨酸/苏氨酸激酶(BRAF)、肿瘤蛋白53 (TP53)、腺瘤性息肉病大肠杆菌和微卫星不稳定性(MSI)等分子特征受到了更多的关注。本研究使用计算机断层扫描(CT)、磁共振成像(MRI)和18F-FDG正电子发射断层扫描(PET)/CT结合放射学和定量分析来预测结直肠癌的分子变化,使用各种统计方法分析结构、最大标准摄取值和MTV等特征。在39项研究中,从这些图像中提取的特征与分子变化之间存在显著关系。采用不同的方法测量受试者工作特征曲线下的面积,以预测KRAS、MSI、BRAF和TP53的改变,平均分别为78.8%、81%、80%和71%。结论:本综述强调了放射基因组学在通过非侵入性成像方式(如CT、MRI和18F-FDG PET/CT)预测结直肠癌分子改变方面的潜力。对41项研究的分析显示了对关键改变的适当预测,如KRAS, NRAS, BRAF, TP53和MSI,突出了放射电子学和纹理特征在提高预测准确性方面的前景。
{"title":"Image Analysis as tool for Predicting Colorectal Cancer Molecular Alterations: A Scoping Review.","authors":"Saman Mohammadpour, Hassan Emami, Reza Rabiei, Azamossadat Hosseini, Hamid Moghaddasi, Fariborz Faeghi, Rafat Bagherzadeh","doi":"10.4274/mirt.galenos.2024.86402","DOIUrl":"10.4274/mirt.galenos.2024.86402","url":null,"abstract":"<p><strong>Objectives: </strong>Among the most important diagnostic indicators of colorectal cancer; however, measuring molecular alterations are invasive and expensive. This study aimed to investigate the application of image processing to predict molecular alterations in colorectal cancer.</p><p><strong>Methods: </strong>In this scoping review, we searched for relevant literature by searching the Web of Science, Scopus, and PubMed databases. The method of selecting the articles and reporting the findings was according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses; moreover, the Strengthening the Reporting of Observational Studies in Epidemiology checklist was used to assess the quality of the studies.</p><p><strong>Results: </strong>Sixty seven out of 2,223 articles, 67 were relevant to the aim of the study, and finally 41 studies with sufficient quality were reviewed. The prediction of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Neuroblastoma RAS Viral (NRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), Tumor Protein 53 (TP53), Adenomatous Polyposis Coli, and microsatellite instability (MSI) with the help of image analysis has received more attention than other molecular characteristics. The studies used computed tomography (CT), magnetic resonance imaging (MRI), and <sup>18</sup>F-FDG positron emission tomography (PET)/CT with radionics and quantitative analysis to predict molecular alterations in colorectal cancer, analyzing features like texture, maximum standard uptake value, and MTV using various statistical methods. In 39 studies, there was a significant relationship between the features extracted from these images and molecular alterations. Different modalities were used to measure the area under the receiver operating characteristic curve for predicting the alterations in KRAS, MSI, BRAF, and TP53, with an average of 78, 81, 80 and 71%, respectively.</p><p><strong>Conclusion: </strong>This scoping review underscores the potential of radiogenomics in predicting molecular alterations in colorectal cancer through non-invasive imaging modalities, like CT, MRI, and <sup>18</sup>F-FDG PET/CT. The analysis of 41 studies showed the appropriate prediction of key alterations, such as KRAS, NRAS, BRAF, TP53, and MSI, highlighting the promise of radionics and texture features in enhancing predictive accuracy.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"10-25"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.68095
Zeynep Işık, Cansu Küçüker, Murat Fani Bozkurt
Omphalocele is a congenital abdominal wall defect with herniation of abdominal viscera into a sac. Tc-99m DMSA renal cortical scan is a functional imaging technique used for detecting parenchymal defects, mostly in patients with recurrent urinary tract infection as well as congenital renal abnormalities. Renal anomalies are known to accompany omphalocele. In this retrospective study, we present a case of cephalad renal ectopia as observed on Tc-99m DMSA scintigraphy in a patient with omphalocele due to a large hernia sac containing most of the liver; and we review the renal abnormalities associated with omphalocele in the literature.
{"title":"Unexpected Detection of Cephalad Renal Ectopia Due to Large Omphalocele Containing the Liver on Tc-99m DMSA Scintigraphy.","authors":"Zeynep Işık, Cansu Küçüker, Murat Fani Bozkurt","doi":"10.4274/mirt.galenos.2024.68095","DOIUrl":"10.4274/mirt.galenos.2024.68095","url":null,"abstract":"<p><p>Omphalocele is a congenital abdominal wall defect with herniation of abdominal viscera into a sac. Tc-99m DMSA renal cortical scan is a functional imaging technique used for detecting parenchymal defects, mostly in patients with recurrent urinary tract infection as well as congenital renal abnormalities. Renal anomalies are known to accompany omphalocele. In this retrospective study, we present a case of cephalad renal ectopia as observed on Tc-99m DMSA scintigraphy in a patient with omphalocele due to a large hernia sac containing most of the liver; and we review the renal abnormalities associated with omphalocele in the literature.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"85-87"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-07DOI: 10.4274/mirt.galenos.2024.59365
Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu
Objectives: This study aimed to investigate the ability of radiomics features extracted from magnetic resonance imaging (MRI) images to differentiate between responders and non-responders for hepatocellular carcinoma (HCC) cases who received Y-90 transarterial radioembolization treatment.
Methods: Thirty-six cases of HCC who underwent MRI scans after Y-90 radioembolization were included in this study. Tumors were segmented from MRI T2 images, and then 87 radiomic features were extracted through the LIFEx package software. Treatment response was determined 9 months after treatment through the modified response evaluation criteria in solid tumours (mRECIST).
Results: According to mRECIST, 28 cases were responders and 8 cases were non-responders. Two radiomics features, "Grey Level Size Zone Matrix (GLSZM)-Small Zone Emphasis" and "GLSZM-Normalized Zone Size Non-Uniformity", were the radiomics features that could predict treatment response with the area under curve (AUC)= 0.71, sensitivity= 0.93, and specificity= 0.62 for both features. Whereas the other 4 features (kurtosis, intensity histogram root mean square, neighbourhood gray-tone difference matrix strength, and GLSZM normalized grey level non-uniformity) have a relatively lower but acceptable discrimination ability range from AUC= 0.6 to 0.66.
Conclusion: MRI radiomics analysis could be used to assess the treatment response for HCC cases treated with Y-90 radioembolization.
{"title":"Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.","authors":"Mennaallah Mahmoud, Ko-Han Lin, Rheun-Chuan Lee, Chien-An Liu","doi":"10.4274/mirt.galenos.2024.59365","DOIUrl":"10.4274/mirt.galenos.2024.59365","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the ability of radiomics features extracted from magnetic resonance imaging (MRI) images to differentiate between responders and non-responders for hepatocellular carcinoma (HCC) cases who received Y-90 transarterial radioembolization treatment.</p><p><strong>Methods: </strong>Thirty-six cases of HCC who underwent MRI scans after Y-90 radioembolization were included in this study. Tumors were segmented from MRI T2 images, and then 87 radiomic features were extracted through the LIFEx package software. Treatment response was determined 9 months after treatment through the modified response evaluation criteria in solid tumours (mRECIST).</p><p><strong>Results: </strong>According to mRECIST, 28 cases were responders and 8 cases were non-responders. Two radiomics features, \"Grey Level Size Zone Matrix (GLSZM)-Small Zone Emphasis\" and \"GLSZM-Normalized Zone Size Non-Uniformity\", were the radiomics features that could predict treatment response with the area under curve (AUC)= 0.71, sensitivity= 0.93, and specificity= 0.62 for both features. Whereas the other 4 features (kurtosis, intensity histogram root mean square, neighbourhood gray-tone difference matrix strength, and GLSZM normalized grey level non-uniformity) have a relatively lower but acceptable discrimination ability range from AUC= 0.6 to 0.66.</p><p><strong>Conclusion: </strong>MRI radiomics analysis could be used to assess the treatment response for HCC cases treated with Y-90 radioembolization.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 3","pages":"156-166"},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-07DOI: 10.4274/mirt.galenos.2024.39269
Kemal Ünal, Levent Güner, Erkan Vardareli
Objectives: The aim of our study was to evaluate the cooccurrence of capsular liver lesions along with peritoneal carcinomatosis and hematogenous metastases in other regions of the body in ovarian cancer patients on follow-up F-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) studies.
Methods: Consecutive 18F-FDG PET/CT studies of 54 women with ovarian cancer between August 2012 and January 2020 and a total of 192 scans were analysed retrospectively. All patients had at least one hepatic and/or capsular lesion with high 18F-FDG uptake and at least two PET/CT examinations.
Results: According to interpretation, of 54 patients with hepatic or capsular lesions, 44 (81.4%), 5 (9.3%) and 5 (9.3%) of them were concluded as perihepatic implants, hematogenous liver metastases and both, respectively. Accompanying peritoneal carcinomatosis on follow-up PET/CT images was found in 42 (95.4%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Extrahepatic hematogenous organ metastases on follow-up PET/CT images were seen in 4 (9.0%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Lungs, bones, spleen and brain were detected metastases sites.
Conclusion: Cooccurrence of peritoneal carcinomatosis in other regions of abdomen was found to be higher in comparison to hematogenous organ metastases on consecutive PET/CT studies of ovarian cancer patients with capsular liver lesions. The primary opinion of the nuclear medicine physician is essential along with the other patient data for differential diagnosis and treatment approach in this particular patient group.
{"title":"Cooccurrence of Capsular Liver Lesions Along with Peritoneal Carcinomatosis and Hematogenous Metastases in Ovarian Cancer Patients on Consecutive <sup>18</sup>F-FDG PET/CT Studies.","authors":"Kemal Ünal, Levent Güner, Erkan Vardareli","doi":"10.4274/mirt.galenos.2024.39269","DOIUrl":"10.4274/mirt.galenos.2024.39269","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of our study was to evaluate the cooccurrence of capsular liver lesions along with peritoneal carcinomatosis and hematogenous metastases in other regions of the body in ovarian cancer patients on follow-up F-18 fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) studies.</p><p><strong>Methods: </strong>Consecutive <sup>18</sup>F-FDG PET/CT studies of 54 women with ovarian cancer between August 2012 and January 2020 and a total of 192 scans were analysed retrospectively. All patients had at least one hepatic and/or capsular lesion with high <sup>18</sup>F-FDG uptake and at least two PET/CT examinations.</p><p><strong>Results: </strong>According to interpretation, of 54 patients with hepatic or capsular lesions, 44 (81.4%), 5 (9.3%) and 5 (9.3%) of them were concluded as perihepatic implants, hematogenous liver metastases and both, respectively. Accompanying peritoneal carcinomatosis on follow-up PET/CT images was found in 42 (95.4%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Extrahepatic hematogenous organ metastases on follow-up PET/CT images were seen in 4 (9.0%) and 3 (60%) patients with solely capsular lesions and solely hematogenous liver metastases, respectively. Lungs, bones, spleen and brain were detected metastases sites.</p><p><strong>Conclusion: </strong>Cooccurrence of peritoneal carcinomatosis in other regions of abdomen was found to be higher in comparison to hematogenous organ metastases on consecutive PET/CT studies of ovarian cancer patients with capsular liver lesions. The primary opinion of the nuclear medicine physician is essential along with the other patient data for differential diagnosis and treatment approach in this particular patient group.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 3","pages":"174-178"},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: The purpose of this study was to investigate whether 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters have a role in differentiating invasive mucinous lung adenocarcinoma (IMA) from lepidic predominant lung adenocarcinoma (LPA). Additionally, we compared the 18F-FDG-PET/CT features between survivors and non-survivors.
Methods: Tumors were divided into 2 groups according to CT appearance: Group 1: nodular-type tumor; group 2: mass- or pneumonic-type tumor. Unilateral and bilateral multifocal diseases were detected. Clinicopathological characteristics and PET/CT findings were compared between IMAs and LPAs, as well as between survivors and non-survivors.
Results: We included 43 patients with IMA and 14 with LPA. Tumor size (p=0.003), incidence of mass/pneumonic type (p=0.011), and bilateral lung involvement (p=0.049) were higher in IMAs than in LPAs. IMAs had more advanced T, M, and Tumor, Node, and Metastasis stages than in LPAs (p=0.048, p=0.049, and p=0.022, respectively). There was no statistically significant difference in maximum standardized uptake value (SUVmax) between the IMA and LPA (p=0.078). The SUV was significantly lower in the nodular group than in the mass/pneumonic-type group (p=0.0001). A total of 11 patients died, of whom SUVmax values were significantly higher in these patients (p=0.031). Male gender (p=0.0001), rate of stage III-IV (p=0.0001), T3-T4 (p=0.021), M1 stages (p=0.0001), multifocality (p=0.0001), and bilateral lung involvement (p=0.0001) were higher in non-survivor.
Conclusions: Although CT images were useful for the differential diagnosis of LPAs and IMAs, SUVmax was not helpful for differentiation of these 2 groups. However, both 18F-FDG uptake and CT findings may play an important role in predicting prognosis in these patients.
研究目的本研究旨在探讨18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)参数是否有助于区分浸润性粘液性肺腺癌(IMA)和鳞状上皮型肺腺癌(LPA)。此外,我们还比较了存活者和非存活者的 18F-FDG-PET/CT 特征:方法:根据CT表现将肿瘤分为两组:第一组:结节型肿瘤;第二组:肿块型或气肿型肿瘤。检测单侧和双侧多灶性疾病。比较了 IMA 和 LPA 以及存活者和非存活者的临床病理特征和 PET/CT 结果:结果:我们纳入了 43 名 IMA 患者和 14 名 LPA 患者。IMA患者的肿瘤大小(p=0.003)、肿块/肺型的发生率(p=0.011)和双肺受累(p=0.049)均高于LPA患者。与LPA相比,IMA的T期、M期、肿瘤期、结节期和转移期更为晚期(分别为p=0.048、p=0.049和p=0.022)。IMA和LPA的最大标准化摄取值(SUVmax)差异无统计学意义(P=0.078)。结节组的 SUV 值明显低于肿块/气肿型组(P=0.0001)。共有 11 名患者死亡,其中这些患者的 SUVmax 值明显更高(P=0.031)。男性(p=0.0001)、III-IV期(p=0.0001)、T3-T4期(p=0.021)、M1期(p=0.0001)、多发(p=0.0001)和双肺受累(p=0.0001)在非存活患者中的比例较高:结论:虽然CT图像有助于鉴别诊断LPA和IMA,但SUVmax并不能帮助区分这两类患者。然而,18F-FDG 摄取和CT结果可能在预测这些患者的预后方面发挥重要作用。
{"title":"Impacts of <sup>18</sup>F-FDG PET/CT Parameters on Differential Diagnosis and Outcome of Patients with Primary Invasive Mucinous and Lepidic Predominant Adenocarcinoma of the Lung.","authors":"Ebru Tatcı, Özlem Özmen, Derya Kızılgöz, Funda Demirağ, Seçkin Bilgiç","doi":"10.4274/mirt.galenos.2024.24571","DOIUrl":"10.4274/mirt.galenos.2024.24571","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to investigate whether <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) parameters have a role in differentiating invasive mucinous lung adenocarcinoma (IMA) from lepidic predominant lung adenocarcinoma (LPA). Additionally, we compared the <sup>18</sup>F-FDG-PET/CT features between survivors and non-survivors.</p><p><strong>Methods: </strong>Tumors were divided into 2 groups according to CT appearance: Group 1: nodular-type tumor; group 2: mass- or pneumonic-type tumor. Unilateral and bilateral multifocal diseases were detected. Clinicopathological characteristics and PET/CT findings were compared between IMAs and LPAs, as well as between survivors and non-survivors.</p><p><strong>Results: </strong>We included 43 patients with IMA and 14 with LPA. Tumor size (p=0.003), incidence of mass/pneumonic type (p=0.011), and bilateral lung involvement (p=0.049) were higher in IMAs than in LPAs. IMAs had more advanced T, M, and Tumor, Node, and Metastasis stages than in LPAs (p=0.048, p=0.049, and p=0.022, respectively). There was no statistically significant difference in maximum standardized uptake value (SUV<sub>max</sub>) between the IMA and LPA (p=0.078). The SUV was significantly lower in the nodular group than in the mass/pneumonic-type group (p=0.0001). A total of 11 patients died, of whom SUV<sub>max</sub> values were significantly higher in these patients (p=0.031). Male gender (p=0.0001), rate of stage III-IV (p=0.0001), T3-T4 (p=0.021), M1 stages (p=0.0001), multifocality (p=0.0001), and bilateral lung involvement (p=0.0001) were higher in non-survivor.</p><p><strong>Conclusions: </strong>Although CT images were useful for the differential diagnosis of LPAs and IMAs, SUV<sub>max</sub> was not helpful for differentiation of these 2 groups. However, both <sup>18</sup>F-FDG uptake and CT findings may play an important role in predicting prognosis in these patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"33 3","pages":"147-155"},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-17DOI: 10.4274/mirt.galenos.2024.57984
Ç. Soydal, M. H. Baltacıoğlu, M. Araz, Burak Demir, E. Dursun, S. Taşkın, N. O. Küçük, F. Ortaç
{"title":"Prognostic Importance of 18F-FDG Positron Emission Tomography in Uterine Cervical Cancer","authors":"Ç. Soydal, M. H. Baltacıoğlu, M. Araz, Burak Demir, E. Dursun, S. Taşkın, N. O. Küçük, F. Ortaç","doi":"10.4274/mirt.galenos.2024.57984","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.57984","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" 8","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141828285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-17DOI: 10.4274/mirt.galenos.2024.02259
Melis Oflas, Duygu Has Şimşek, S. Kuyumcu, Murat Yılmaz Kıran, Y. Şanlı
The diagnostic performance of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for primary kidney tumors is limited. Nevertheless, 18 F-FDG PET/CT is valuable for staging renal cell carcinoma (RCC) when suspected metastases coexist, as one-third of patients with RCC have distant metastases upon diagnosis. Herein, we present a 53-year-old male patient with extensive 18 F-FDG-avid metastatic lesions and an 18 F-FDG-avid renal mass, which later revealed RCC
{"title":"The Utility of 18F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma","authors":"Melis Oflas, Duygu Has Şimşek, S. Kuyumcu, Murat Yılmaz Kıran, Y. Şanlı","doi":"10.4274/mirt.galenos.2024.02259","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.02259","url":null,"abstract":"The diagnostic performance of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for primary kidney tumors is limited. Nevertheless, 18 F-FDG PET/CT is valuable for staging renal cell carcinoma (RCC) when suspected metastases coexist, as one-third of patients with RCC have distant metastases upon diagnosis. Herein, we present a 53-year-old male patient with extensive 18 F-FDG-avid metastatic lesions and an 18 F-FDG-avid renal mass, which later revealed RCC","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" 28","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141830422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-17DOI: 10.4274/mirt.galenos.2024.26486
Chaymae Bensaid, Salah Oueriagli Nabih, Kenza Bouzidi, O. Sahel, Y. Benameur, A. Doudouh
{"title":"Diagnosis of Atypical Medullary Metastasis in Melanoma Using 18F-FDG PET/CT","authors":"Chaymae Bensaid, Salah Oueriagli Nabih, Kenza Bouzidi, O. Sahel, Y. Benameur, A. Doudouh","doi":"10.4274/mirt.galenos.2024.26486","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.26486","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141830344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-10DOI: 10.4274/mirt.galenos.2024.74875
Büşra Özdemir Günay, Burak Günay, N. Can, Funda Üstün
{"title":"A Rare Malignancy; Primary Peritoneal Serous Carcinoma in Men with 18F-FDG PET/CT and Histopathology","authors":"Büşra Özdemir Günay, Burak Günay, N. Can, Funda Üstün","doi":"10.4274/mirt.galenos.2024.74875","DOIUrl":"https://doi.org/10.4274/mirt.galenos.2024.74875","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"40 21","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141660353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}